Everforth Inc quarterly report, Q1 FY2004

Business Context and Reporting Period

Company: On Assignment, Inc. (Note: Input metadata referenced "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: A leading provider of skilled temporary professionals to clients in the science and healthcare industries. The company operates two segments: Healthcare Staffing (Nurse Travel, Medical Financial, and Allied) and Lab Support (scientific staffing for biotechnology, pharmaceutical, and other industries).

Key Financial Metrics

Metric Q1 2004 Q1 2003
Revenues $46,426,000 $57,825,000
Gross Profit $11,813,000 $15,480,000
Gross Margin 25.4% 26.8%
Operating Loss $(2,536,000) $(863,000)
Net Loss $(1,503,000) $(452,000)
Loss Per Share (Basic/Diluted) $(0.06) $(0.02)
Cash and Cash Equivalents $34,608,000 $29,488,000
Working Capital $52,351,000 N/A
Net Cash from Operating Activities $853,000 $(2,038,000)
Total Debt $0 $0

Material Changes vs. Prior Period

  • Revenue Decline: Total revenues decreased 19.7% to $46.4 million. The Healthcare Staffing segment dropped 19.5% (driven by a 31.4% decrease in temporary professionals on assignment), while the Lab Support segment fell 20.0% due to reduced R&D spending in the biotechnology sector.
  • Widening Operating Loss: Operating loss increased from $863,000 to $2.5 million. While SG&A expenses decreased 12.2% due to prior cost-cutting measures, the decline in revenue caused SG&A as a percentage of revenue to rise from 28.3% to 30.9%.
  • Cost of Services: Decreased 18.3% to $34.6 million, tracking with the reduction in staff on assignment. However, the cost of services as a percentage of revenue increased to 74.6% due to higher workers' compensation expenses and payroll taxes.
  • Cash Flow Improvement: The company generated positive operating cash flow of $853,000, a significant improvement over the $2.0 million outflow in the prior year, driven by a reduction in accounts receivable and prepaid expenses.

Guidance, Outlook, and Risks

  • Management Outlook: Management does not expect to generate net income for the full year 2004 due to the timing of resource investments associated with a revitalization plan and the current performance of the Medical Financial and Allied lines.
  • Strategic Focus: The company is implementing a revitalization plan to grow revenues through organic growth, hiring experienced staffing veterans, and expanding the Lab Support segment internationally (UK, Netherlands, Belgium).
  • Capital Expenditures: The company expects to incur an additional $4.0 million to $4.4 million in capital expenditures over the next nine months, primarily for the PeopleSoft enterprise system and leasehold improvements.
  • Risks and Contingencies:
    • Goodwill Impairment: While no impairment was recorded in Q1 2004, the company previously recorded a $79.9 million impairment charge in Q2 2003. Management continues to evaluate goodwill for impairment.
    • Liquidity: Liquidity relies on cash flows from operations. A decrease in demand for staffing services could adversely impact liquidity.
    • Seasonality: Results are subject to seasonal fluctuations, with reduced demand typically occurring during the holiday season and summer months.

Investor Verification Checklist

  • Revenue Recovery: Verify if the "revitalization plan" is successfully reversing the 20% revenue decline in both Healthcare and Lab Support segments.
  • Medical Financial Segment: Monitor the Medical Financial and Allied line, which saw a 46.4% revenue drop and is cited as a primary reason for the lack of 2004 profitability.
  • Capital Expenditure Timing: Confirm the timing and ROI of the $4.4 million planned investment in PeopleSoft and infrastructure.
  • Workers' Compensation Costs: Track the trend of workers' compensation expenses, which contributed to the widening gross margin compression.
  • Goodwill Valuation: Review future filings for any new triggers requiring goodwill impairment testing given the remaining $43.5 million balance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.